Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
43.06
+0.07 (+0.16%)
Streaming Delayed Price
Updated: 2:32 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gsk Plc ADR
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
27
28
Next >
Recent Stock Purchases For March 2023
March 25, 2023
As readers may know by now, I make stock purchases every single month, no matter what is going on in the world. This month, I went heavier than I normally do, deploying over $3,000. Let's take a look.
Via
Talk Markets
GSK Stock Skids On Judge's New Ruling As Zantac Trial Looms
March 24, 2023
A trial this summer will examine one Zantac user's cancer.
Via
Investor's Business Daily
This Is What Whales Are Betting On GSK
March 23, 2023
Via
Benzinga
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
March 21, 2023
Via
Benzinga
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
March 20, 2023
Reuters
Via
Benzinga
Daily Stock Analysis: GSK
March 17, 2023
By my dogcatcher ideal, this is a proper time to buy GSK shares, based on their dividends for 2023.
Via
Talk Markets
How Is The Market Feeling About GSK?
March 15, 2023
Via
Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
March 20, 2023
Via
Benzinga
3 Pharma Stocks That Could Benefit from Global Healthcare Trends
March 17, 2023
The best pharma stocks to buy are those that are poised to be greatly boosted by drugs that are well-positioned to become blockbusters.
Via
InvestorPlace
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?
March 17, 2023
An approved RSV vaccine could be the next big thing for these companies.
Via
The Motley Fool
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
March 15, 2023
GSK Plc's (NYSE: GSK) top scientist, Tony Wood, who took the helm of R&D last August, says the R&D department is now delivering results. Wood said he is de-emphasizing R&D in oncology and that the R&D...
Via
Benzinga
3 High Dividend Stocks With Attractive Total Return Potential
March 10, 2023
In the current economic environment, it is crucial for investors to prioritize quality, reliable dividend stocks and high total returns.
Via
InvestorPlace
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
March 08, 2023
These companies aren't working on a vaccine, but a monoclonal antibody.
Via
Investor's Business Daily
Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock?
March 05, 2023
This vaccine candidate could help tackle the respiratory syncytial virus.
Via
The Motley Fool
March 2023 Stock Considerations
March 04, 2023
The calendar has turned, and a new trading month is upon us. 2023 is flying by as two months are already in the books, and that fact simply highlights the importance of staying invested in the stock...
Via
Talk Markets
FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK's Candidate Soon After Pfizer's
March 02, 2023
Via
Benzinga
3 Crucial Things to Know About Moderna Right Now
February 27, 2023
This vaccine leader is preparing for a post-pandemic world.
Via
The Motley Fool
GSK's Relief For Few Months, First Trial Claiming Zantac Caused Cancer Pushed Into Late 2023
February 24, 2023
The first scheduled trial expected next week, related to GSK Plc's (NYSE: GSK) Zantac associated with cancer, has been postponed, likely by several months.
Via
Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields
February 23, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows
February 23, 2023
Via
Benzinga
Intel and 9 Other Companies With Dividend Cuts in 2023
February 22, 2023
Intel announced that it would cut its dividend by a whopping 66%. Here are nine other companies that have also seen dividend cuts this year.
Via
InvestorPlace
My 3 Biggest Stock Market Predictions for March
February 21, 2023
These three trends will likely drive revenue and share prices.
Via
The Motley Fool
EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue
February 15, 2023
Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among...
Via
Benzinga
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals
February 15, 2023
Via
Benzinga
Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out
February 14, 2023
Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.
Via
Benzinga
Dividend Income Update For January 2023
February 12, 2023
Without rehashing the wild ride we experienced in the market over the last few months, I could find comfort in one thing: my dividends (even if dividend cuts are on the table these days). Let's see how...
Via
Talk Markets
Week In Review: CANbridge In-Licenses Gene Therapy For Rare Disease From UMass
February 11, 2023
CANbridge Pharma exercised an option for global rights to a novel second-gen gene therapy from UMass Chan medical school. Additionally, Zhimeng Biopharma signed an agreement to out-license global...
Via
Talk Markets
FDA AdComm Votes In Favor Of GSK's Jemperli Single Arm Trial Plan For Rectal Cancer Setting
February 10, 2023
Via
Benzinga
FDA Grants Complete Approval For GSK's Jemperli For Endometrial Cancer
February 10, 2023
Via
Benzinga
February 2023 Stock Considerations
February 05, 2023
With a new trading month already in full swing, it is time to highlight some of my potential stock purchases. While the market had a nice bounce in recent months, there is still no shortage of stocks...
Via
Talk Markets
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
27
28
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.